News

MacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results
First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination ...
The Manila Times1d
MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results
Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients ...
Targeted Oncology2d
Novel Combinations Highlight Treatment Advances in Melanoma
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...